Clinical Trials
14 trialsNCT02653976 2024-01-26
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.
Phase 2 Completed
NCT01435863 2015-08-13
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.
Phase 1 Completed
NCT01689220 2014-09-04
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Solasia Pharma K.K.
Phase 1 Completed
NCT00423306 2013-11-14
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
Alaunos Therapeutics
Phase 2 Unknown
NCT00423644 2013-11-14
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
Alaunos Therapeutics
Phase 2 Unknown
NCT00509782 2012-08-01
Phase I Trial of ZIO-101 in Patients With Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00303199 2012-07-19
Study of ZIO-101 in Multiple Myeloma
Alaunos Therapeutics
Phase 1/2 Completed
NCT00421213 2012-07-19
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Alaunos Therapeutics
Phase 2 Completed
NCT00591396 2012-07-19
A Phase I Trial of ZIO-101 in Solid Tumors
Alaunos Therapeutics
Phase 1 Completed
NCT00591422 2012-07-19
Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Alaunos Therapeutics
Phase 1 Unknown
NCT00592046 2012-07-19
A Phase I Trial of ZIO-101 in Hematologic Cancers
Alaunos Therapeutics
Phase 1 Completed
NCT00592163 2012-07-19
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Alaunos Therapeutics
Phase 1 Unknown
NCT01139346 2012-07-19
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
Alaunos Therapeutics
Phase 1 Completed
NCT01139359 2012-07-19
Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma
Alaunos Therapeutics
Phase 1 Withdrawn